Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Anemia in cancer: some pathophysiological aspects.

Mario Dicato1

  • 1Haematology-Oncology, Luxembourg Medical Center, Luxembourg. dicato.mario@chl.lu

The Oncologist
|March 11, 2003
PubMed
Summary

Cancer-related anemia affects over 30% of patients, often caused by cytokine imbalance. Increasing erythropoietin levels can correct anemia and improve quality of life in many patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Antileukemic potential of methylated indolequinone MAC681 through immunogenic necroptosis and PARP1 degradation.

Biomarker research·2024
Same author

ATP1A1/BCL2L1 predicts the response of myelomonocytic and monocytic acute myeloid leukemia to cardiac glycosides.

Leukemia·2023
Same author

Enhancing personalized immune checkpoint therapy by immune archetyping and pharmacological targeting.

Pharmacological research·2023
Same author

Marine Polyether Phycotoxin Palytoxin Induces Apoptotic Cell Death via Mcl-1 and Bcl-2 Downregulation.

Marine drugs·2023
Same author

Phytochemical Screening and Antioxidant and Cytotoxic Effects of <i>Acacia macrostachya</i>.

Plants (Basel, Switzerland)·2021
Same author

Anti-Leukemic Properties of Aplysinopsin Derivative EE-84 Alone and Combined to BH3 Mimetic A-1210477.

Marine drugs·2021

Area of Science:

  • Oncology
  • Hematology
  • Immunology

Background:

  • Anemia is a common complication in cancer patients, affecting over 30%.
  • Cancer-associated anemia is frequently linked to cytokine imbalances, particularly tumor necrosis factor-alpha.
  • Tumor necrosis factor-alpha can inhibit the effectiveness of erythropoietin, a key hormone in red blood cell production.

Purpose of the Study:

  • To investigate the role of cytokine imbalance in cancer-related anemia.
  • To evaluate the efficacy of pharmacologically increasing erythropoietin levels in anemic cancer patients.
  • To assess the impact of anemia treatment on patient quality of life.

Main Methods:

  • Review of existing studies on cancer-associated anemia and cytokine profiles.
  • Analysis of data from patients treated with pharmacologic erythropoietin.
  • Assessment of quality of life measures pre- and post-treatment.

Main Results:

  • Pharmacological elevation of erythropoietin levels successfully corrected anemia in approximately 50% of treated cancer patients.
  • The underlying mechanism involves counteracting the inhibitory effects of cytokines like tumor necrosis factor-alpha.
  • Significant improvements in quality of life were observed in patients responding to erythropoietin therapy.

Conclusions:

  • Erythropoietin-based therapy is an effective strategy for managing anemia in a substantial proportion of cancer patients.
  • Targeting cytokine-mediated suppression of erythropoiesis holds promise for future therapeutic approaches.
  • Improving anemia through erythropoietin treatment leads to a notable enhancement in the quality of life for cancer patients.

Related Experiment Videos